安徽省司尔特肥业股份有限公司公告 安徽省司尔特肥业股份有限公司监事会对 《董事会对会计师事务所出具的保留意见的财务审计报告的专 项说明》的意见 大华会计师事务所（特殊普通合伙）就安徽省司尔特肥业股份有限公司（以 下简称"公司"）公司 2023 年度财务报告出具了审计报告（报告编号：大华审 字[2024]0011004073 号），该审计报告为保留意见的审计报告。公司董事会就 上述事项出具了专项说明。根据中国证券监督管理委员会《公开发行证券的公司 信息披露编报规则第 14 号——非标准审计意见及其涉及事项的处理》和《深圳 证券交易所股票上市规则》的相关要求，公司监事会对《董事会对会计师事务所 出具的保留意见的财务审计报告的专项说明》进行了认真地审核，并提出如下书 面审核意见： 监事会认为，公司董事会对会计师事务所出具的保留意见的财务审计报告的 专项说明符合中国证监会、深圳证券交易所相关规定的要求及公司实际情况。监 事会同意董事会对大华会计师事务所（特殊普通合伙）出具的保留意见的财务审 计报告的说明，将持续关注并监督董事会和管理层对相关工作的开展情况，维护 公司及全体股东利益。 安徽省司尔特肥业股份有限公司监事会 ...

安徽省司尔特肥业股份有限公司 审计报告 大华审字[2024]0011004073 号 大 华 会 计 师 事 务 所 (特殊普通合伙 ) Da Hua Certified Public Accountants（Special General Partnership） 安徽省司尔特肥业股份有限公司 审计报告及财务报表 （2023 年 1 月 1 日至 2023 年 12 月 31 日止） | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 审计报告 | | 1-7 | | 二、 | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-97 | 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 ...

安徽省司尔特肥业股份有限公司公告 证券代码：002538 证券简称：司尔特 公告编号：2024-4 安徽省司尔特肥业股份有限公司 第六届董事会第十三次会议决议公告 本公司及其董事会全体成员保证公告内容真实、完整和准确，不存在虚假记 载、误导性陈述或重大遗漏。 安徽省司尔特肥业股份有限公司（以下简称"公司"或"本公司"）第六届董事 会第十三次会议于 2024 年 4 月 23 日在安徽省合肥市汇金大厦 26 楼会议室以现 场结合通讯方式召开，会议通知于 2024 年 4 月 13 日以专人送达及电子邮件方式 送达。本次会议应到董事 9 名，实到董事 9 名；公司全体监事和高级管理人员列 席本次会议，会议由公司董事长朱国全先生主持。本次会议符合《公司法》《公 司章程》的规定，会议的召集、召开合法有效。经与会董事审议表决，形成如下 决议： 一、审议通过《2023 年度董事会工作报告》 投票结果：全体董事以 9 票赞成，0 票反对，0 票弃权通过该议案。 本议案尚需提交公司 2023 年年度股东大会审议。 报告的具体内容详见同时在巨潮资讯网上披露的《安徽省司尔特肥业股份 有限公司 2023 年年度报告全文》之"第三节 ...

安徽省司尔特肥业股份有限公司公告 安徽省司尔特肥业股份有限公司 公司章程修订对照表 本公司及其董事会全体成员保证公告内容真实、完整和准确，不存在虚假 记载、误导性陈述或重大遗漏。 根据中国证监会发布的《上市公司独立董事管理办法》《上市公司章程指 引》和《上市公司监管指引第 3 号——上市公司现金分红》》以及《深圳证券 交股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作》等有关规定，并结合公司实际情况，对《公司章程》进行了 | 原公司章程条款 | | | 修改后的公司章程条款 | | | --- | --- | --- | --- | --- | | 第二十条 股东持股比例为： | | | 第二十条 股东持股比例为： | | | 股东名称 | 持股数量 | 持股比例（%） | 持股比例 股东名称 持股数量（股） | | | （股） | | | （%） | | | 无限售流 97.70 通股 | 833,958,488 | | 无限售流通 853,555,763 | 100.00 | | | | | 股 | | | 限售流通股 2.30 | 19,597,275 | | 合计 ...

安徽省司尔特肥业股份有限公司 安徽省司尔特肥业股份有限公司 董事会议事规则 (2024年4月修订) 第一章 总 则 第一条 为规范董事会议事方式与程序，提高董事会议事效率，保证董事会 决策的科学性，切实行使董事会的职权，维护公司利益，根据《中华人民共和国公 司法》（以下简称"《公司法》"）《上市公司独立董事管理办法》和《安徽省司尔 特肥业股份有限公司章程》(以下简称"《公司章程》") 的有关规定，制定本规则。 第二条 董事会对股东大会负责，并依据国家有关法律、法规和《公司章程》 行使职权。 第三条 本规则对公司全体董事具有约束力。 第二章 董 事 第四条 董事应当遵守法律、法规和《公司章程》的规定，忠实履行职责维 护公司利益。当其自身的利益与公司和股东的利益相冲突时，应当以公司和股东的 最大利益为行为准则，并保证： （一）在其职责范围内行使权利，不得越权； （二）除经《公司章程》规定或者股东大会在知情的情况下批准，不得同 公司订立合同或者进行交易； （三）不得利用内幕信息为自己或他人谋取利益； （四）不得自营或者为他人经营与公司同类的业务或者从事损害公司利益 的活动； （五）不得利用职权收受贿赂或者其他非法收 ...

安徽省司尔特肥业股份有限公司公告 安徽省司尔特肥业股份有限公司 关于向公安机关报案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 近日，安徽省司尔特肥业股份有限公司（以下简称"公司"）发现，公司 审计部副部长黄席利等可能涉嫌职务侵占犯罪。在黄席利等拒不配合公司调查 并提出辞职后，公司先后向宣城市公安局经济犯罪侦查支队、宁国市公安局经 济犯罪侦查大队报案。2024 年 1 月 17 日，公司收到宁国市公安局出具的《受 案回执》，案件已受理，受案登记表文号为宁公（经）受案字〔2024〕155 号。 因本次报案案件尚未正式立案，公司目前无法判断案件对本期利润或期后 利润等的影响。公司将全力配合公安机关的侦查工作，维护公司和全体股东利 益，并将根据案件的进展情况，严格按照有关法律、法规及规范性文件的要求 及时履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 特此公告。 安徽省司尔特肥业股份有限公司董事会 二〇二四年一月十八日 证券代码：002538 证券简称：司尔特 公告编号：2024-2 1 ...

安徽省司尔特肥业股份有限公司公告 特此公告。 安徽省司尔特肥业股份有限公司董事会 二〇二四年一月九日 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 安徽省司尔特肥业股份有限公司（以下简称"公司"）董事会于2024年1月6 日收到公司副总经理方君女士提交的书面辞职报告，方君女士原定任期为三 年，至公司第六届董事会任期届满为止，现因个人家庭原因申请辞去公司副总 经理职务，方君女士辞职后将不再担任公司任何职务。 根据《公司法》《公司章程》等有关规定，方君女士的辞职不会对公司的 生产运营产生影响。其辞职报告自送达董事会之日起生效。 截至本公告披露日，方君女士未直接持有公司股份，不存在应当履行而未 履行的承诺事项。 证券代码：002538 证券简称：司尔特 公告编号：2024-1 安徽省司尔特肥业股份有限公司 ...

二、备查文件 关于全资子公司通过高新技术企业认定的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 一、主要内容 安徽省司尔特肥业股份有限公司（以下简称"公司"）下属全资子公司安徽 司尔特化肥科技有限公司（以下简称"化肥科技"）于近日从全国高新技术企业 认定管理工作领导小组办公室发布的《对安徽省认定机构 2023 年认定报备的第 二批高新技术企业进行备案的公告》获悉，化肥科技被列入安徽省认定机构 2023 年认定报备的第二批高新技术企业备案名单，被认定为高新技术企业，证书编号： GR202334005440，发证日期：2023 年 11 月 30 日。 根据《中华人民共和国企业所得税法》以及国家对高新技术企业的相关税收 优惠政策，化肥科技在通过高新技术企业认定后，连续三年（即 2023 年、2024 年、 2025 年）享受高新技术企业所得税优惠政策，即按 15%的税率缴纳企业所得税。 化肥科技获得该事项认定是对公司在技术研发和自主创新方面的肯定和鼓 励，有助于公司进一步规范经营、科学化管理，提高公司抗风险能力、整体创新 能力和综合竞争力。 安徽省司尔特肥业 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥1,316,913,343.76, representing a 110.58% increase compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥23,123,477.54, a decrease of 286.07% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥34,630,154.52, down 539.52% from the previous year[4] - Total operating revenue for Q3 2023 was CNY 3,034,951,872.96, a decrease of 16.1% compared to CNY 3,616,656,018.52 in the same period last year[22] - Net profit for Q3 2023 was CNY 123,192,854.55, a significant decline of 75.5% from CNY 503,548,484.85 in Q3 2022[24] - Total comprehensive income for the period was CNY 123,192,854.55, compared to CNY 503,548,484.85 in the previous period, indicating a significant decrease[26] - Basic and diluted earnings per share were both CNY 0.14, down from CNY 0.59 in the previous period[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,541,299,762.58, a decrease of 5.79% from the end of the previous year[4] - The company's total assets decreased to CNY 6,541,299,762.58 from CNY 6,943,496,181.91 year-over-year[21] - Total liabilities decreased to CNY 1,290,460,762.01 from CNY 1,597,173,490.89, indicating improved financial stability[21] - The total equity attributable to shareholders was CNY 5,250,839,000.57, down from CNY 5,346,322,691.02[21] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥64,434,914.69, a decline of 122.81% compared to the same period last year[4] - Cash inflow from operating activities totaled CNY 2,748,690,177.46, a decrease from CNY 3,022,412,787.31 in the previous period[28] - Net cash outflow from operating activities was CNY 64,434,914.69, compared to a net inflow of CNY 282,513,166.17 in the previous period[29] - Cash inflow from investment activities was CNY 3,335,053,121.62, up from CNY 2,740,975,267.82 in the previous period[29] - Net cash flow from investment activities was CNY 10,606,389.82, a recovery from a net outflow of CNY 138,579,803.58 in the previous period[29] - Cash inflow from financing activities was CNY 430,000,000.00, while cash outflow was CNY 436,659,381.70, resulting in a net cash outflow of CNY 436,659,381.70[29] - The ending cash and cash equivalents balance was CNY 527,539,990.38, down from CNY 593,174,678.16 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 47.715 million[11] - The largest shareholder, Guogou Industrial Holdings, holds 21.33% of shares, amounting to 182,050,800 shares, with 179,530,000 shares pledged[11] - The top ten shareholders hold a significant portion of shares, with the top two alone accounting for 29.63%[11] Research and Development - Research and development expenses for the first nine months of 2023 were ¥59,988,574.30, down 36.58% from the same period in 2022[9] - The company reported a decrease in research and development expenses to CNY 59,988,574.30 from CNY 94,590,601.60, suggesting a potential shift in focus[24] Future Plans - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[8] - The company plans to invest 1.72448 billion RMB in the construction of a phosphate-fluoride new material integrated industrial park in Guizhou Province, with a construction period of 36 months[15] - The company is actively pursuing market expansion through strategic investments and partnerships in the health and agricultural sectors[14] Financial Management - The company reported a decrease in financial expenses, with interest expenses dropping to CNY 6,673,709.58 from CNY 19,972,727.23, reflecting better cost management[24] - The weighted average return on net assets was -0.44% for the reporting period, down 0.70% year-on-year[4] Audit and Accounting Standards - The company did not undergo an audit for the third quarter report[31] - The company has not adopted the new accounting standards starting from 2023[30]

Financial Performance - The company's revenue for Q3 2023 reached ¥1,316,913,343.76, representing a 110.58% increase compared to the same period last year[4] - The net profit attributable to shareholders was -¥23,123,477.54, a decrease of 286.07% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥45,096,409.32, down 672.36% from the previous year[4] - Total operating revenue for Q3 2023 was CNY 3,034,951,872.96, a decrease of 16.1% compared to CNY 3,616,656,018.52 in the same period last year[22] - Net profit for Q3 2023 was CNY 123,192,854.55, a significant decline of 75.5% from CNY 503,548,484.85 in Q3 2022[24] - Total comprehensive income for the period was CNY 123,192,854.55, compared to CNY 503,548,484.85 in the previous period, indicating a significant decrease[26] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,541,299,762.58, a decrease of 5.79% compared to the end of the previous year[4] - The company's total assets decreased to CNY 6,541,299,762.58 from CNY 6,943,496,181.91 year-over-year[21] - Total liabilities decreased to CNY 1,290,460,762.01 from CNY 1,597,173,490.89, indicating improved financial stability[21] - The total equity attributable to shareholders decreased to CNY 5,250,839,000.57 from CNY 5,346,322,691.02, reflecting the impact of reduced profits[21] Cash Flow - Cash flow from operating activities showed a net outflow of -¥64,434,914.69, a decrease of 122.81% compared to the same period last year[4] - Net cash flow from operating activities was CNY -64,434,914.69, a decline from CNY 282,513,166.17 in the previous period[29] - Cash inflow from investment activities totaled CNY 3,335,053,121.62, compared to CNY 2,740,975,267.82 in the previous period, showing an increase[29] - Net cash flow from investment activities was CNY 10,606,389.82, recovering from a negative CNY 138,579,803.58 in the previous period[29] - Total cash outflow from financing activities was CNY 436,659,381.70, compared to CNY 802,588,096.47 in the previous period, indicating a reduction[29] - The company reported a cash inflow of CNY 430,000,000.00 from borrowing activities during the current period[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 47.715 million[11] - The largest shareholder, Guogou Industrial Holdings, holds 21.33% of shares, amounting to 182,050,800 shares, with 179,530,000 shares pledged[11] - The top ten shareholders hold a significant portion of shares, with the top two alone accounting for 29.63% of total shares[11] Research and Development - Research and development expenses for the first nine months of 2023 were ¥59,988,574.30, down 36.58% from the same period in 2022[9] - The company reported a decrease in research and development expenses to CNY 59,988,574.30 from CNY 94,590,601.60, suggesting a potential shift in focus[24] Future Plans and Investments - The company plans to invest 1.72448 billion RMB in the construction of a phosphate-fluoride new material integrated industrial park in Guizhou Province, with a construction period of 36 months[15] - The project will include a 600,000 tons/year phosphate ore dressing facility and a 400,000 tons/year sulfuric acid production facility among other installations[15] - The company plans to enhance market expansion efforts and invest in new product development in the upcoming quarters[20] - The company is actively pursuing market expansion through strategic investments and partnerships in the health and materials sectors[14] Operational Efficiency - The company aims to improve operational efficiency and reduce costs further in response to market challenges[20] - Total operating costs for Q3 2023 were CNY 2,914,326,831.86, down from CNY 3,051,351,590.89, reflecting a cost reduction strategy[22] Miscellaneous - As of September 30, 2023, the company's cash and cash equivalents amount to 538.91 million RMB, down from 1.02216 billion RMB at the beginning of the year[18] - The company has provided 110 million RMB in working capital support to a subsidiary, with 40 million RMB remaining to be repaid by the end of 2024[15] - The company has signed a management agreement for its subsidiary, entrusting operations to a local hospital for a period extending until December 31, 2029[16] - The company’s accounts receivable as of September 30, 2023, is 55.41 million RMB, slightly down from 59.74 million RMB at the beginning of the year[18] - The company has not undergone an audit for the third quarter report[31] - The company has not adopted the new accounting standards for the current year[30]